Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Болезни шейки матки – неочевидные последствия недостаточности мышц тазового дна
Болезни шейки матки – неочевидные последствия недостаточности мышц тазового дна
Оразов М.Р, Токтар Л.Р, Каримова Г.А., Пак В., Ли К, Муллина И.А. Болезни шейки матки – неочевидные последствия недостаточности мышц тазового дна. Гинекология. 2021; 23 (2): 131–136.
DOI: 10.26442/20795696.2021.2.200778
DOI: 10.26442/20795696.2021.2.200778
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре литературы представлены отечественные и зарубежные данные, касающиеся взаимосвязи недостаточности тазового дна (НТД) и заболеваний шейки матки, найденные в системах PubMed, Scopus, Embase и eLibrary за последние 10 лет. В первую очередь, эта взаимосвязь реализуется вследствие нарушений биоценоза влагалища как самого раннего клинического проявления НТД. Описаны распространенность НТД, классификация, факторы риска развития НТД. Приведены основные методы лечения и их осложнения. Представлены данные об изменении биоценоза влагалища при НТД. Уделено внимание риску развития цервикальной интраэпителиальной неоплазии и рака шейки матки при НТД.
Ключевые слова: недостаточность мышц тазового дна, пролапс, рак шейки матки, цервикальная интраэпителиальная неоплазия, микробиота, микробиом, биоценоз влагалища, лактобактерии
Key words: pelvic floor dysfunction, prolapse, cervical cancer, cervical intraepithelial neoplasia, microbiota, microbiome, vaginal biocenosis, lactobacilli
Ключевые слова: недостаточность мышц тазового дна, пролапс, рак шейки матки, цервикальная интраэпителиальная неоплазия, микробиота, микробиом, биоценоз влагалища, лактобактерии
________________________________________________
Key words: pelvic floor dysfunction, prolapse, cervical cancer, cervical intraepithelial neoplasia, microbiota, microbiome, vaginal biocenosis, lactobacilli
Полный текст
Список литературы
1. Weintraub AY, Glinter H, Marcus-Braun N. Narrative review of the epidemiology, diagnosis and pathophysiology of pelvic organ prolapse. Int Braz J Urol. 2020; 46 (1): 5–14. DOI: 10.1590/S1677-5538.IBJU.2018.0581
2. Barber MD, Maher C. Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J. 2013; 24 (11): 1783–90. DOI: 10.1007/s00192-013-2169-9
3. Радзинский В.Е., Оразов М.Р., Токтар Л.Р., и др. Перинеология. Эстетическая гинекология. Под ред. Радзинского В.Е. М.: StatusPraesens, 2020 [Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)].
4. Tegerstedt G, Maehle-Schmidt M, Nyrén O, Hammarström M. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. Int Urogynecol J Pelvic Floor Dysfunct. 2005; 16 (6): 497–503. DOI: 10.1007/s00192-005-1326-1
5. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008; 300 (11): 1311–6. DOI: 10.1001/jama.300.11.1311
6. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020; 19 (5). DOI: 10.1186/s12941-020-0347-4
7. Shah AD, Kohli N, Rajan SS, Hoyte L. The age distribution, rates, and types of surgery for pelvic organ prolapse in the USA. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19 (3): 421–8.
8. Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123 (1): 141–8.
9. Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol. 2009; 114 (6): 1278–83. DOI: 10.1097/AOG.0b013e3181c2ce96
10. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996; 175 (1): 10–7.
11. Madhu C, Swift S, Moloney-Geany S, Drake MJ. How to use the Pelvic Organ Prolapse Quantification (POP-Q) system? Neurourol Urodyn. 2018; 37 (S6): S39–43. DOI: 10.1002/nau.23740
12. Dietz HP, Mann K. What is clinically relevant prolapse? An attempt at defining cutoffs for the clinical assessment of pelvic organ descent. Int Urogynecol J. 2014; 25: 451–5.
13. Hallock JL, Handa VL. The Epidemiology of Pelvic Floor Disorders and Childbirth: An Update. Obstet Gynecol Clin North Am. 2016; 43 (1): 1–13. DOI: 10.1016/j.ogc.2015.10.008
14. Scott AJ, Alexander JL, Merrifield CA, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019; 68: 1624–32.
15. Veit-Rubin N, De Tayrac R, Cartwright R, et al. Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourol Urodyn. 2019; 38 (8): 2255–63. DOI: 10.1002/nau.24129
16. Chen C, Song X, Wei W, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017; 8 (1): 875.
17. Stone L. Infection: Vaginal microbiota and infectious infertility. Nat Rev Urol. 2018; 15 (3): 136.
18. Li H, Zang Y, Wang C, et al. The Interaction Between Microorganisms, Metabolites, and Immune System in the Female Genital Tract Microenvironment. Front Cell Infect Microbiol. 2020; 10: 609488.
19. Li Y, Yu T, Yan H, et al. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies. Infect Drug Resist. 2020; 13: 1213–20. DOI: 10.2147/IDR.S210615
20. Morais IMC, Cordeiro AL, Teixeira GS, et al. Biological and physico chemical properties of biosurfactants produced by Lactobacillus jen senii P6A and Lactobacillus gasseri P65. Microb. Cell Fact. 2017; 16 (1): 155.
21. Xu J, Bian G, Zheng M, et al. Fertility factors affect the vaginal microbiome in women of reproductive age. Am J Reprod Immunol. 2020; 83 (4): e13220.
22. Memon HU, Handa VL. Vaginal childbirth and pelvic floor disorders. Womens Health. 2013; 9 (3): 265–77.
23. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020; 222 (3): 219–23.
24. Thomas-White KJ, Gao X, Lin H, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J. 2018; 29 (12): 1797–805. DOI: 10.1007/s00192-018-3767-3
25. Радзинский В.Е., Тигиева А.В. Вульвовагинальные болезни: возможности патогенетической терапии. Эффективная фармакотерапия. 2014; 45: 38–43 [Radzinskii VE, Tigieva AV. Vul’vovaginal’nye bolezni: vozmozhnosti patogeneticheskoi terapii. Effektivnaia farmakoterapiia. 2014; 45: 38–43 (in Russian)].
26. Аполихина И.А., Гасанова Г.Ф., Додова Е.Г., Горбунова Е.А. Роль ацидофильных лактобактерий в противорецидивной терапии бактериального вагиноза и вульвовагинального кандидоза: восстановление нормоценоза влагалища. Вопр. гинекологии, акушерства и перинатологии. 2015; 14 (1): 5–10 [Apolikhina IA, Gasanova GF, Dodova EG, Gorbunova EA. Rol’ atsidofil’nykh laktobakterii v protivoretsidivnoi terapii bakterial’nogo vaginoza i vul’vovaginal’nogo kandidoza: vosstanovlenie normotsenoza vlagalishcha. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (1): 5–10 (in Russian)].
27. Тихомиров А.Л. Профилактика вагинальных дисбиотических состояний с применением штаммов ацидофильных лактобактерий у пациенток после гинекологических операций. Вопр. гинекологии, акушерства и перинатологии. 2015; 14 (3): 5–8 [Tikhomirov AL. Profilaktika vaginal’nykh disbioticheskikh sostoianii s primeneniem shtammov atsidofil’nykh laktobakterii u patsientok posle ginekologicheskikh operatsii. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (3): 5–8 (in Russian)].
28. de Castro EB, Brito LGO, Giraldo PC, Teatin Juliato CR. Does the Vaginal Flora Modify When a Synthetic Mesh is Used for Genital Prolapse Repair in Postmenopausal Women? A Pilot, Randomized Controlled Study. Female Pelvic Med Reconstr Surg. 2019; 25 (4): 284–8. DOI: 10.1097/SPV.0000000000000539
29. Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy. Maturitas. 2019; 121: 86–92. DOI: 10.1016/j.maturitas.2018.11.016; PMID: 30509753
30. Barber MD. Pelvic organ prolapse. BMJ. 2016; 354: i3853. DOI: 10.1136/bmj.i3853
31. Cheung RYK, Lee JHS, Lee LL, et al. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial. Obstet Gynecol. 2016; 128 (1): 73–80. DOI: 10.1097/AOG.0000000000001489
32. Гинекология: учебник. Под ред. Радзинского В.Е., Фукс А.М.
М.: ГЭОТАР-Медиа, 2016 [Gynecology: textbook. Ed. Radzinsky VE, Fuks AM. Moscow: GEOTAR-Media, 2016 (in Russian)].
33. Радзинский В.Е., Оразов М.Р., Токтар Л.Р., и др. Перинеология. Эстетическая гинекология. Под ред. Радзинского В.Е. М.: StatusPraesens, 2020 [Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)].
34. Alnaif B, Drutz HP. Bacterial vaginosis increases in pessary users. Int Urogynecol J Pelvic Floor Dysfunct. 2000; 11 (4): 219–23. DOI: 10.1007/pl00004026
35. Coelho SCA, Giraldo PC, Florentino JO, et al. Can the Pessary Use Modify the Vaginal Microbiological Flora? A Cross-sectional Study. Rev Bras Ginecol Obstet 2017; 39 (4): 169–74. DOI: 10.1055/s-0037-1601437
36. Thomas SG, Sato HRN, Glantz JC, et al. Prevalence of symptomatic pelvic floor disorders among gynecologic oncology patients. Obstet Gynecol. 2013; 122 (5): 976–80. DOI: 10.1097/AOG.0b013e3182a7ef3c
37. Yoshimura K, Morotomi N, Fukuda K, et al. Effects of pelvic organ prolapse ring pessary therapy on intravaginal microbial flora. Int Urogynecol J. 2016; 27 (2): 219–27. DOI: 10.1007/s00192-015-2811-9
38. Garrett WS. Cancer and the microbiota. Science. 2015; 348 (6230): 80–6. DOI: 10.1126/science.aaa4972
39. Meng C, Bai C, Brown TD, et al. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018; 16 (1): 33–49. DOI: 10.1016/j.gpb.2017.06.002
40. Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33 (6): 954–64. DOI: 10.1016/j.ccell.2018.03.004
41. Chen D, Wu J, Jin D, et al. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019; 145 (8): 2021–31. DOI: 10.1002/ijc.32003.
42. Castanheira CP, Sallas ML, Nunes RAL, et al. Microbiome and Cervical Cancer. Pathobiology. 2021; 88: 187–97. DOI: 10.1159/000511477
43. Curty G, de Carvalho PS, Soares MA. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. Int J Mol Sci. 2019; 21 (1). DOI: 10.3390/ijms21010222
44. Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020; 202 (2): 323–7. DOI: 10.1007/s00203-019-01747-4
45. Van Der Veer C, Hertzberger RY, Bruisten SM, et al. Comparative genomics of human Lactobacillus crispatus isolates reveals genes for glycosylation and glycogen degradation: implications for in vivo dominance. Microbiome. 2019; 7 (1): 49.
46. Thomas RM, Jobin C. The Microbiome and Cancer: Is the “Oncobiome” Mirage Real? Trends Cancer. 2015; 1 (1): 24–35. DOI: 10.1016/j.trecan.2015.07.005
47. Mitra A, MacIntyre DA, Marchesi JR, et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 2016; 4 (1): 58. DOI: 10.1186/s40168-016-0203-0
48. Fang G, Hong L, Liu C, et al. Oxidative status of cardinal ligament in pelvic organ prolapse. Exp Ther Med. 2018; 16 (4): 3293–302. DOI: 10.3892/etm.2018.6633
49. Geoffrion R, Louie K, Hyakutake MT, et al. Study of Prolapse-Induced Cervical Elongation. J Obstet Gynaecol Can. 2016; 38 (3): 265–9. DOI: 10.1016/j.jogc.2016.01.008
50. Elbiaa AAM, Abdelazim IA, Farghali MM, et al. Unexpected premalignant gynecological lesions in women undergoing vaginal hysterectomy for utero-vaginal prolapse. Prz menopauzalny = Menopause Rev. 2015; 14 (3): 188–91. DOI: 10.5114/pm.2015.54344
51. Grigoriadis T, Valla A, Zacharakis D, et al. Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy? Int Urogynecol J. 2015; 26 (3): 421–5. DOI: 10.1007/s00192-014-2516-5
52. Mahajan G, Kotru M, Batra M, et al. Usefulness of histopathological examination in uterine prolapse specimens. Aust N Z J Obstet Gynaecol. 2011; 51 (5): 403–5. DOI: 10.1111/j.1479-828X.2011.01337.x
53. Chung CP, Lee SJ, Wakabayashi MT. Uterine and cervical cancer with irreducible pelvic organ prolapse. Am J Obstet Gynecol. 2018; 219 (6): 621–2. DOI: 10.1016/j.ajog.2018.05.021
54. Babarović E, Sladoljev K, Perin E, et al. Primary Carcinosarcoma of the Vagina Associated With Differentiated Squamous Intraepithelial Neoplasia in a Patient With Complete Uterine Prolapse: Case Report and Review of the Literature. Int J Surg Pathol. 2018; 26 (4): 370–6. DOI: 10.1177/1066896917745592
55. Martin C, Hong L, Siddighi S. What is hiding behind the pessary? Int Urogynecol J. 2013; 24 (5): 873–5. DOI: 10.1007/s00192-012-1864-2
56. Iavazzo C, Vorgias G, Vecchini G, et al. Vaginal carcinoma in a completely prolapsed uterus. A case report. Arch Gynecol Obstet. 2007; 275 (6): 503–5.
DOI: 10.1007/s00404-006-0284-2
57. Reimer D, Sztankay A, Steppan I, et al. Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. Eur J Gynaecol Oncol. 2008; 29 (3): 272–5.
58. Ramaseshan AS, Felton J, Roque D, et al. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. Int Urogynecol J. 2018; 29 (4): 459–76. DOI: 10.1007/s00192-017-3467-4
2. Barber MD, Maher C. Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J. 2013; 24 (11): 1783–90. DOI: 10.1007/s00192-013-2169-9
3. Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)
4. Tegerstedt G, Maehle-Schmidt M, Nyrén O, Hammarström M. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. Int Urogynecol J Pelvic Floor Dysfunct. 2005; 16 (6): 497–503. DOI: 10.1007/s00192-005-1326-1
5. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008; 300 (11): 1311–6. DOI: 10.1001/jama.300.11.1311
6. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020; 19 (5). DOI: 10.1186/s12941-020-0347-4
7. Shah AD, Kohli N, Rajan SS, Hoyte L. The age distribution, rates, and types of surgery for pelvic organ prolapse in the USA. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19 (3): 421–8.
8. Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123 (1): 141–8.
9. Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol. 2009; 114 (6): 1278–83. DOI: 10.1097/AOG.0b013e3181c2ce96
10. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996; 175 (1): 10–7.
11. Madhu C, Swift S, Moloney-Geany S, Drake MJ. How to use the Pelvic Organ Prolapse Quantification (POP-Q) system? Neurourol Urodyn. 2018; 37 (S6): S39–43. DOI: 10.1002/nau.23740
12. Dietz HP, Mann K. What is clinically relevant prolapse? An attempt at defining cutoffs for the clinical assessment of pelvic organ descent. Int Urogynecol J. 2014; 25: 451–5.
13. Hallock JL, Handa VL. The Epidemiology of Pelvic Floor Disorders and Childbirth: An Update. Obstet Gynecol Clin North Am. 2016; 43 (1): 1–13. DOI: 10.1016/j.ogc.2015.10.008
14. Scott AJ, Alexander JL, Merrifield CA, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019; 68: 1624–32.
15. Veit-Rubin N, De Tayrac R, Cartwright R, et al. Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourol Urodyn. 2019; 38 (8): 2255–63. DOI: 10.1002/nau.24129
16. Chen C, Song X, Wei W, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017; 8 (1): 875.
17. Stone L. Infection: Vaginal microbiota and infectious infertility. Nat Rev Urol. 2018; 15 (3): 136.
18. Li H, Zang Y, Wang C, et al. The Interaction Between Microorganisms, Metabolites, and Immune System in the Female Genital Tract Microenvironment. Front Cell Infect Microbiol. 2020; 10: 609488.
19. Li Y, Yu T, Yan H, et al. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies. Infect Drug Resist. 2020; 13: 1213–20. DOI: 10.2147/IDR.S210615
20. Morais IMC, Cordeiro AL, Teixeira GS, et al. Biological and physico chemical properties of biosurfactants produced by Lactobacillus jen senii P6A and Lactobacillus gasseri P65. Microb. Cell Fact. 2017; 16 (1): 155.
21. Xu J, Bian G, Zheng M, et al. Fertility factors affect the vaginal microbiome in women of reproductive age. Am J Reprod Immunol. 2020; 83 (4): e13220.
22. Memon HU, Handa VL. Vaginal childbirth and pelvic floor disorders. Womens Health. 2013; 9 (3): 265–77.
23. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020; 222 (3): 219–23.
24. Thomas-White KJ, Gao X, Lin H, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J. 2018; 29 (12): 1797–805. DOI: 10.1007/s00192-018-3767-3
25. Radzinskii VE, Tigieva AV. Vul’vovaginal’nye bolezni: vozmozhnosti patogeneticheskoi terapii. Effektivnaia farmakoterapiia. 2014; 45: 38–43 (in Russian)
26. Apolikhina IA, Gasanova GF, Dodova EG, Gorbunova EA. Rol’ atsidofil’nykh laktobakterii v protivoretsidivnoi terapii bakterial’nogo vaginoza i vul’vovaginal’nogo kandidoza: vosstanovlenie normotsenoza vlagalishcha. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (1): 5–10 (in Russian)
27. Tikhomirov AL. Profilaktika vaginal’nykh disbioticheskikh sostoianii s primeneniem shtammov atsidofil’nykh laktobakterii u patsientok posle ginekologicheskikh operatsii. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (3): 5–8 (in Russian)
28. de Castro EB, Brito LGO, Giraldo PC, Teatin Juliato CR. Does the Vaginal Flora Modify When a Synthetic Mesh is Used for Genital Prolapse Repair in Postmenopausal Women? A Pilot, Randomized Controlled Study. Female Pelvic Med Reconstr Surg. 2019; 25 (4): 284–8. DOI: 10.1097/SPV.0000000000000539
29. Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy. Maturitas. 2019; 121: 86–92. DOI: 10.1016/j.maturitas.2018.11.016; PMID: 30509753
30. Barber MD. Pelvic organ prolapse. BMJ. 2016; 354: i3853. DOI: 10.1136/bmj.i3853
31. Cheung RYK, Lee JHS, Lee LL, et al. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial. Obstet Gynecol. 2016; 128 (1): 73–80. DOI: 10.1097/AOG.0000000000001489
32. Gynecology: textbook. Ed. Radzinsky VE, Fuks AM. Moscow: GEOTAR-Media, 2016 (in Russian)
33. Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)
34. Alnaif B, Drutz HP. Bacterial vaginosis increases in pessary users. Int Urogynecol J Pelvic Floor Dysfunct. 2000; 11 (4): 219–23. DOI: 10.1007/pl00004026
35. Coelho SCA, Giraldo PC, Florentino JO, et al. Can the Pessary Use Modify the Vaginal Microbiological Flora? A Cross-sectional Study. Rev Bras Ginecol Obstet 2017; 39 (4): 169–74. DOI: 10.1055/s-0037-1601437
36. Thomas SG, Sato HRN, Glantz JC, et al. Prevalence of symptomatic pelvic floor disorders among gynecologic oncology patients. Obstet Gynecol. 2013; 122 (5): 976–80. DOI: 10.1097/AOG.0b013e3182a7ef3c
37. Yoshimura K, Morotomi N, Fukuda K, et al. Effects of pelvic organ prolapse ring pessary therapy on intravaginal microbial flora. Int Urogynecol J. 2016; 27 (2): 219–27. DOI: 10.1007/s00192-015-2811-9
38. Garrett WS. Cancer and the microbiota. Science. 2015; 348 (6230): 80–6. DOI: 10.1126/science.aaa4972
39. Meng C, Bai C, Brown TD, et al. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018; 16 (1): 33–49. DOI: 10.1016/j.gpb.2017.06.002
40. Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33 (6): 954–64. DOI: 10.1016/j.ccell.2018.03.004
41. Chen D, Wu J, Jin D, et al. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019; 145 (8): 2021–31. DOI: 10.1002/ijc.32003.
42. Castanheira CP, Sallas ML, Nunes RAL, et al. Microbiome and Cervical Cancer. Pathobiology. 2021; 88: 187–97. DOI: 10.1159/000511477
43. Curty G, de Carvalho PS, Soares MA. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. Int J Mol Sci. 2019; 21 (1). DOI: 10.3390/ijms21010222
44. Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020; 202 (2): 323–7. DOI: 10.1007/s00203-019-01747-4
45. Van Der Veer C, Hertzberger RY, Bruisten SM, et al. Comparative genomics of human Lactobacillus crispatus isolates reveals genes for glycosylation and glycogen degradation: implications for in vivo dominance. Microbiome. 2019; 7 (1): 49.
46. Thomas RM, Jobin C. The Microbiome and Cancer: Is the “Oncobiome” Mirage Real? Trends Cancer. 2015; 1 (1): 24–35. DOI: 10.1016/j.trecan.2015.07.005
47. Mitra A, MacIntyre DA, Marchesi JR, et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 2016; 4 (1): 58. DOI: 10.1186/s40168-016-0203-0
48. Fang G, Hong L, Liu C, et al. Oxidative status of cardinal ligament in pelvic organ prolapse. Exp Ther Med. 2018; 16 (4): 3293–302. DOI: 10.3892/etm.2018.6633
49. Geoffrion R, Louie K, Hyakutake MT, et al. Study of Prolapse-Induced Cervical Elongation. J Obstet Gynaecol Can. 2016; 38 (3): 265–9. DOI: 10.1016/j.jogc.2016.01.008
50. Elbiaa AAM, Abdelazim IA, Farghali MM, et al. Unexpected premalignant gynecological lesions in women undergoing vaginal hysterectomy for utero-vaginal prolapse. Prz menopauzalny = Menopause Rev. 2015; 14 (3): 188–91. DOI: 10.5114/pm.2015.54344
51. Grigoriadis T, Valla A, Zacharakis D, et al. Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy? Int Urogynecol J. 2015; 26 (3): 421–5. DOI: 10.1007/s00192-014-2516-5
52. Mahajan G, Kotru M, Batra M, et al. Usefulness of histopathological examination in uterine prolapse specimens. Aust N Z J Obstet Gynaecol. 2011; 51 (5): 403–5. DOI: 10.1111/j.1479-828X.2011.01337.x
53. Chung CP, Lee SJ, Wakabayashi MT. Uterine and cervical cancer with irreducible pelvic organ prolapse. Am J Obstet Gynecol. 2018; 219 (6): 621–2. DOI: 10.1016/j.ajog.2018.05.021
54. Babarović E, Sladoljev K, Perin E, et al. Primary Carcinosarcoma of the Vagina Associated With Differentiated Squamous Intraepithelial Neoplasia in a Patient With Complete Uterine Prolapse: Case Report and Review of the Literature. Int J Surg Pathol. 2018; 26 (4): 370–6. DOI: 10.1177/1066896917745592
55. Martin C, Hong L, Siddighi S. What is hiding behind the pessary? Int Urogynecol J. 2013; 24 (5): 873–5. DOI: 10.1007/s00192-012-1864-2
56. Iavazzo C, Vorgias G, Vecchini G, et al. Vaginal carcinoma in a completely prolapsed uterus. A case report. Arch Gynecol Obstet. 2007; 275 (6): 503–5.
DOI: 10.1007/s00404-006-0284-2
57. Reimer D, Sztankay A, Steppan I, et al. Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. Eur J Gynaecol Oncol. 2008; 29 (3): 272–5.
58. Ramaseshan AS, Felton J, Roque D, et al. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. Int Urogynecol J. 2018; 29 (4): 459–76. DOI: 10.1007/s00192-017-3467-4
2. Barber MD, Maher C. Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J. 2013; 24 (11): 1783–90. DOI: 10.1007/s00192-013-2169-9
3. Радзинский В.Е., Оразов М.Р., Токтар Л.Р., и др. Перинеология. Эстетическая гинекология. Под ред. Радзинского В.Е. М.: StatusPraesens, 2020 [Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)].
4. Tegerstedt G, Maehle-Schmidt M, Nyrén O, Hammarström M. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. Int Urogynecol J Pelvic Floor Dysfunct. 2005; 16 (6): 497–503. DOI: 10.1007/s00192-005-1326-1
5. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008; 300 (11): 1311–6. DOI: 10.1001/jama.300.11.1311
6. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020; 19 (5). DOI: 10.1186/s12941-020-0347-4
7. Shah AD, Kohli N, Rajan SS, Hoyte L. The age distribution, rates, and types of surgery for pelvic organ prolapse in the USA. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19 (3): 421–8.
8. Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123 (1): 141–8.
9. Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol. 2009; 114 (6): 1278–83. DOI: 10.1097/AOG.0b013e3181c2ce96
10. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996; 175 (1): 10–7.
11. Madhu C, Swift S, Moloney-Geany S, Drake MJ. How to use the Pelvic Organ Prolapse Quantification (POP-Q) system? Neurourol Urodyn. 2018; 37 (S6): S39–43. DOI: 10.1002/nau.23740
12. Dietz HP, Mann K. What is clinically relevant prolapse? An attempt at defining cutoffs for the clinical assessment of pelvic organ descent. Int Urogynecol J. 2014; 25: 451–5.
13. Hallock JL, Handa VL. The Epidemiology of Pelvic Floor Disorders and Childbirth: An Update. Obstet Gynecol Clin North Am. 2016; 43 (1): 1–13. DOI: 10.1016/j.ogc.2015.10.008
14. Scott AJ, Alexander JL, Merrifield CA, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019; 68: 1624–32.
15. Veit-Rubin N, De Tayrac R, Cartwright R, et al. Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourol Urodyn. 2019; 38 (8): 2255–63. DOI: 10.1002/nau.24129
16. Chen C, Song X, Wei W, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017; 8 (1): 875.
17. Stone L. Infection: Vaginal microbiota and infectious infertility. Nat Rev Urol. 2018; 15 (3): 136.
18. Li H, Zang Y, Wang C, et al. The Interaction Between Microorganisms, Metabolites, and Immune System in the Female Genital Tract Microenvironment. Front Cell Infect Microbiol. 2020; 10: 609488.
19. Li Y, Yu T, Yan H, et al. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies. Infect Drug Resist. 2020; 13: 1213–20. DOI: 10.2147/IDR.S210615
20. Morais IMC, Cordeiro AL, Teixeira GS, et al. Biological and physico chemical properties of biosurfactants produced by Lactobacillus jen senii P6A and Lactobacillus gasseri P65. Microb. Cell Fact. 2017; 16 (1): 155.
21. Xu J, Bian G, Zheng M, et al. Fertility factors affect the vaginal microbiome in women of reproductive age. Am J Reprod Immunol. 2020; 83 (4): e13220.
22. Memon HU, Handa VL. Vaginal childbirth and pelvic floor disorders. Womens Health. 2013; 9 (3): 265–77.
23. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020; 222 (3): 219–23.
24. Thomas-White KJ, Gao X, Lin H, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J. 2018; 29 (12): 1797–805. DOI: 10.1007/s00192-018-3767-3
25. Радзинский В.Е., Тигиева А.В. Вульвовагинальные болезни: возможности патогенетической терапии. Эффективная фармакотерапия. 2014; 45: 38–43 [Radzinskii VE, Tigieva AV. Vul’vovaginal’nye bolezni: vozmozhnosti patogeneticheskoi terapii. Effektivnaia farmakoterapiia. 2014; 45: 38–43 (in Russian)].
26. Аполихина И.А., Гасанова Г.Ф., Додова Е.Г., Горбунова Е.А. Роль ацидофильных лактобактерий в противорецидивной терапии бактериального вагиноза и вульвовагинального кандидоза: восстановление нормоценоза влагалища. Вопр. гинекологии, акушерства и перинатологии. 2015; 14 (1): 5–10 [Apolikhina IA, Gasanova GF, Dodova EG, Gorbunova EA. Rol’ atsidofil’nykh laktobakterii v protivoretsidivnoi terapii bakterial’nogo vaginoza i vul’vovaginal’nogo kandidoza: vosstanovlenie normotsenoza vlagalishcha. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (1): 5–10 (in Russian)].
27. Тихомиров А.Л. Профилактика вагинальных дисбиотических состояний с применением штаммов ацидофильных лактобактерий у пациенток после гинекологических операций. Вопр. гинекологии, акушерства и перинатологии. 2015; 14 (3): 5–8 [Tikhomirov AL. Profilaktika vaginal’nykh disbioticheskikh sostoianii s primeneniem shtammov atsidofil’nykh laktobakterii u patsientok posle ginekologicheskikh operatsii. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (3): 5–8 (in Russian)].
28. de Castro EB, Brito LGO, Giraldo PC, Teatin Juliato CR. Does the Vaginal Flora Modify When a Synthetic Mesh is Used for Genital Prolapse Repair in Postmenopausal Women? A Pilot, Randomized Controlled Study. Female Pelvic Med Reconstr Surg. 2019; 25 (4): 284–8. DOI: 10.1097/SPV.0000000000000539
29. Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy. Maturitas. 2019; 121: 86–92. DOI: 10.1016/j.maturitas.2018.11.016; PMID: 30509753
30. Barber MD. Pelvic organ prolapse. BMJ. 2016; 354: i3853. DOI: 10.1136/bmj.i3853
31. Cheung RYK, Lee JHS, Lee LL, et al. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial. Obstet Gynecol. 2016; 128 (1): 73–80. DOI: 10.1097/AOG.0000000000001489
32. Гинекология: учебник. Под ред. Радзинского В.Е., Фукс А.М.
М.: ГЭОТАР-Медиа, 2016 [Gynecology: textbook. Ed. Radzinsky VE, Fuks AM. Moscow: GEOTAR-Media, 2016 (in Russian)].
33. Радзинский В.Е., Оразов М.Р., Токтар Л.Р., и др. Перинеология. Эстетическая гинекология. Под ред. Радзинского В.Е. М.: StatusPraesens, 2020 [Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)].
34. Alnaif B, Drutz HP. Bacterial vaginosis increases in pessary users. Int Urogynecol J Pelvic Floor Dysfunct. 2000; 11 (4): 219–23. DOI: 10.1007/pl00004026
35. Coelho SCA, Giraldo PC, Florentino JO, et al. Can the Pessary Use Modify the Vaginal Microbiological Flora? A Cross-sectional Study. Rev Bras Ginecol Obstet 2017; 39 (4): 169–74. DOI: 10.1055/s-0037-1601437
36. Thomas SG, Sato HRN, Glantz JC, et al. Prevalence of symptomatic pelvic floor disorders among gynecologic oncology patients. Obstet Gynecol. 2013; 122 (5): 976–80. DOI: 10.1097/AOG.0b013e3182a7ef3c
37. Yoshimura K, Morotomi N, Fukuda K, et al. Effects of pelvic organ prolapse ring pessary therapy on intravaginal microbial flora. Int Urogynecol J. 2016; 27 (2): 219–27. DOI: 10.1007/s00192-015-2811-9
38. Garrett WS. Cancer and the microbiota. Science. 2015; 348 (6230): 80–6. DOI: 10.1126/science.aaa4972
39. Meng C, Bai C, Brown TD, et al. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018; 16 (1): 33–49. DOI: 10.1016/j.gpb.2017.06.002
40. Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33 (6): 954–64. DOI: 10.1016/j.ccell.2018.03.004
41. Chen D, Wu J, Jin D, et al. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019; 145 (8): 2021–31. DOI: 10.1002/ijc.32003.
42. Castanheira CP, Sallas ML, Nunes RAL, et al. Microbiome and Cervical Cancer. Pathobiology. 2021; 88: 187–97. DOI: 10.1159/000511477
43. Curty G, de Carvalho PS, Soares MA. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. Int J Mol Sci. 2019; 21 (1). DOI: 10.3390/ijms21010222
44. Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020; 202 (2): 323–7. DOI: 10.1007/s00203-019-01747-4
45. Van Der Veer C, Hertzberger RY, Bruisten SM, et al. Comparative genomics of human Lactobacillus crispatus isolates reveals genes for glycosylation and glycogen degradation: implications for in vivo dominance. Microbiome. 2019; 7 (1): 49.
46. Thomas RM, Jobin C. The Microbiome and Cancer: Is the “Oncobiome” Mirage Real? Trends Cancer. 2015; 1 (1): 24–35. DOI: 10.1016/j.trecan.2015.07.005
47. Mitra A, MacIntyre DA, Marchesi JR, et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 2016; 4 (1): 58. DOI: 10.1186/s40168-016-0203-0
48. Fang G, Hong L, Liu C, et al. Oxidative status of cardinal ligament in pelvic organ prolapse. Exp Ther Med. 2018; 16 (4): 3293–302. DOI: 10.3892/etm.2018.6633
49. Geoffrion R, Louie K, Hyakutake MT, et al. Study of Prolapse-Induced Cervical Elongation. J Obstet Gynaecol Can. 2016; 38 (3): 265–9. DOI: 10.1016/j.jogc.2016.01.008
50. Elbiaa AAM, Abdelazim IA, Farghali MM, et al. Unexpected premalignant gynecological lesions in women undergoing vaginal hysterectomy for utero-vaginal prolapse. Prz menopauzalny = Menopause Rev. 2015; 14 (3): 188–91. DOI: 10.5114/pm.2015.54344
51. Grigoriadis T, Valla A, Zacharakis D, et al. Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy? Int Urogynecol J. 2015; 26 (3): 421–5. DOI: 10.1007/s00192-014-2516-5
52. Mahajan G, Kotru M, Batra M, et al. Usefulness of histopathological examination in uterine prolapse specimens. Aust N Z J Obstet Gynaecol. 2011; 51 (5): 403–5. DOI: 10.1111/j.1479-828X.2011.01337.x
53. Chung CP, Lee SJ, Wakabayashi MT. Uterine and cervical cancer with irreducible pelvic organ prolapse. Am J Obstet Gynecol. 2018; 219 (6): 621–2. DOI: 10.1016/j.ajog.2018.05.021
54. Babarović E, Sladoljev K, Perin E, et al. Primary Carcinosarcoma of the Vagina Associated With Differentiated Squamous Intraepithelial Neoplasia in a Patient With Complete Uterine Prolapse: Case Report and Review of the Literature. Int J Surg Pathol. 2018; 26 (4): 370–6. DOI: 10.1177/1066896917745592
55. Martin C, Hong L, Siddighi S. What is hiding behind the pessary? Int Urogynecol J. 2013; 24 (5): 873–5. DOI: 10.1007/s00192-012-1864-2
56. Iavazzo C, Vorgias G, Vecchini G, et al. Vaginal carcinoma in a completely prolapsed uterus. A case report. Arch Gynecol Obstet. 2007; 275 (6): 503–5.
DOI: 10.1007/s00404-006-0284-2
57. Reimer D, Sztankay A, Steppan I, et al. Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. Eur J Gynaecol Oncol. 2008; 29 (3): 272–5.
58. Ramaseshan AS, Felton J, Roque D, et al. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. Int Urogynecol J. 2018; 29 (4): 459–76. DOI: 10.1007/s00192-017-3467-4
________________________________________________
2. Barber MD, Maher C. Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J. 2013; 24 (11): 1783–90. DOI: 10.1007/s00192-013-2169-9
3. Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)
4. Tegerstedt G, Maehle-Schmidt M, Nyrén O, Hammarström M. Prevalence of symptomatic pelvic organ prolapse in a Swedish population. Int Urogynecol J Pelvic Floor Dysfunct. 2005; 16 (6): 497–503. DOI: 10.1007/s00192-005-1326-1
5. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008; 300 (11): 1311–6. DOI: 10.1001/jama.300.11.1311
6. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020; 19 (5). DOI: 10.1186/s12941-020-0347-4
7. Shah AD, Kohli N, Rajan SS, Hoyte L. The age distribution, rates, and types of surgery for pelvic organ prolapse in the USA. Int Urogynecol J Pelvic Floor Dysfunct. 2008; 19 (3): 421–8.
8. Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014; 123 (1): 141–8.
9. Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol. 2009; 114 (6): 1278–83. DOI: 10.1097/AOG.0b013e3181c2ce96
10. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996; 175 (1): 10–7.
11. Madhu C, Swift S, Moloney-Geany S, Drake MJ. How to use the Pelvic Organ Prolapse Quantification (POP-Q) system? Neurourol Urodyn. 2018; 37 (S6): S39–43. DOI: 10.1002/nau.23740
12. Dietz HP, Mann K. What is clinically relevant prolapse? An attempt at defining cutoffs for the clinical assessment of pelvic organ descent. Int Urogynecol J. 2014; 25: 451–5.
13. Hallock JL, Handa VL. The Epidemiology of Pelvic Floor Disorders and Childbirth: An Update. Obstet Gynecol Clin North Am. 2016; 43 (1): 1–13. DOI: 10.1016/j.ogc.2015.10.008
14. Scott AJ, Alexander JL, Merrifield CA, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019; 68: 1624–32.
15. Veit-Rubin N, De Tayrac R, Cartwright R, et al. Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourol Urodyn. 2019; 38 (8): 2255–63. DOI: 10.1002/nau.24129
16. Chen C, Song X, Wei W, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017; 8 (1): 875.
17. Stone L. Infection: Vaginal microbiota and infectious infertility. Nat Rev Urol. 2018; 15 (3): 136.
18. Li H, Zang Y, Wang C, et al. The Interaction Between Microorganisms, Metabolites, and Immune System in the Female Genital Tract Microenvironment. Front Cell Infect Microbiol. 2020; 10: 609488.
19. Li Y, Yu T, Yan H, et al. Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies. Infect Drug Resist. 2020; 13: 1213–20. DOI: 10.2147/IDR.S210615
20. Morais IMC, Cordeiro AL, Teixeira GS, et al. Biological and physico chemical properties of biosurfactants produced by Lactobacillus jen senii P6A and Lactobacillus gasseri P65. Microb. Cell Fact. 2017; 16 (1): 155.
21. Xu J, Bian G, Zheng M, et al. Fertility factors affect the vaginal microbiome in women of reproductive age. Am J Reprod Immunol. 2020; 83 (4): e13220.
22. Memon HU, Handa VL. Vaginal childbirth and pelvic floor disorders. Womens Health. 2013; 9 (3): 265–77.
23. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020; 222 (3): 219–23.
24. Thomas-White KJ, Gao X, Lin H, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J. 2018; 29 (12): 1797–805. DOI: 10.1007/s00192-018-3767-3
25. Radzinskii VE, Tigieva AV. Vul’vovaginal’nye bolezni: vozmozhnosti patogeneticheskoi terapii. Effektivnaia farmakoterapiia. 2014; 45: 38–43 (in Russian)
26. Apolikhina IA, Gasanova GF, Dodova EG, Gorbunova EA. Rol’ atsidofil’nykh laktobakterii v protivoretsidivnoi terapii bakterial’nogo vaginoza i vul’vovaginal’nogo kandidoza: vosstanovlenie normotsenoza vlagalishcha. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (1): 5–10 (in Russian)
27. Tikhomirov AL. Profilaktika vaginal’nykh disbioticheskikh sostoianii s primeneniem shtammov atsidofil’nykh laktobakterii u patsientok posle ginekologicheskikh operatsii. Vopr. ginekologii, akusherstva i perinatologii. 2015; 14 (3): 5–8 (in Russian)
28. de Castro EB, Brito LGO, Giraldo PC, Teatin Juliato CR. Does the Vaginal Flora Modify When a Synthetic Mesh is Used for Genital Prolapse Repair in Postmenopausal Women? A Pilot, Randomized Controlled Study. Female Pelvic Med Reconstr Surg. 2019; 25 (4): 284–8. DOI: 10.1097/SPV.0000000000000539
29. Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy. Maturitas. 2019; 121: 86–92. DOI: 10.1016/j.maturitas.2018.11.016; PMID: 30509753
30. Barber MD. Pelvic organ prolapse. BMJ. 2016; 354: i3853. DOI: 10.1136/bmj.i3853
31. Cheung RYK, Lee JHS, Lee LL, et al. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial. Obstet Gynecol. 2016; 128 (1): 73–80. DOI: 10.1097/AOG.0000000000001489
32. Gynecology: textbook. Ed. Radzinsky VE, Fuks AM. Moscow: GEOTAR-Media, 2016 (in Russian)
33. Radzinsky VE, Orazov MR, Toktar LR, et al. Perineology. Aesthetic gynecology. Ed. Radzinsky VE. Moscow: StatusPraesens, 2020 (in Russian)
34. Alnaif B, Drutz HP. Bacterial vaginosis increases in pessary users. Int Urogynecol J Pelvic Floor Dysfunct. 2000; 11 (4): 219–23. DOI: 10.1007/pl00004026
35. Coelho SCA, Giraldo PC, Florentino JO, et al. Can the Pessary Use Modify the Vaginal Microbiological Flora? A Cross-sectional Study. Rev Bras Ginecol Obstet 2017; 39 (4): 169–74. DOI: 10.1055/s-0037-1601437
36. Thomas SG, Sato HRN, Glantz JC, et al. Prevalence of symptomatic pelvic floor disorders among gynecologic oncology patients. Obstet Gynecol. 2013; 122 (5): 976–80. DOI: 10.1097/AOG.0b013e3182a7ef3c
37. Yoshimura K, Morotomi N, Fukuda K, et al. Effects of pelvic organ prolapse ring pessary therapy on intravaginal microbial flora. Int Urogynecol J. 2016; 27 (2): 219–27. DOI: 10.1007/s00192-015-2811-9
38. Garrett WS. Cancer and the microbiota. Science. 2015; 348 (6230): 80–6. DOI: 10.1126/science.aaa4972
39. Meng C, Bai C, Brown TD, et al. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018; 16 (1): 33–49. DOI: 10.1016/j.gpb.2017.06.002
40. Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33 (6): 954–64. DOI: 10.1016/j.ccell.2018.03.004
41. Chen D, Wu J, Jin D, et al. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019; 145 (8): 2021–31. DOI: 10.1002/ijc.32003.
42. Castanheira CP, Sallas ML, Nunes RAL, et al. Microbiome and Cervical Cancer. Pathobiology. 2021; 88: 187–97. DOI: 10.1159/000511477
43. Curty G, de Carvalho PS, Soares MA. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. Int J Mol Sci. 2019; 21 (1). DOI: 10.3390/ijms21010222
44. Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020; 202 (2): 323–7. DOI: 10.1007/s00203-019-01747-4
45. Van Der Veer C, Hertzberger RY, Bruisten SM, et al. Comparative genomics of human Lactobacillus crispatus isolates reveals genes for glycosylation and glycogen degradation: implications for in vivo dominance. Microbiome. 2019; 7 (1): 49.
46. Thomas RM, Jobin C. The Microbiome and Cancer: Is the “Oncobiome” Mirage Real? Trends Cancer. 2015; 1 (1): 24–35. DOI: 10.1016/j.trecan.2015.07.005
47. Mitra A, MacIntyre DA, Marchesi JR, et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 2016; 4 (1): 58. DOI: 10.1186/s40168-016-0203-0
48. Fang G, Hong L, Liu C, et al. Oxidative status of cardinal ligament in pelvic organ prolapse. Exp Ther Med. 2018; 16 (4): 3293–302. DOI: 10.3892/etm.2018.6633
49. Geoffrion R, Louie K, Hyakutake MT, et al. Study of Prolapse-Induced Cervical Elongation. J Obstet Gynaecol Can. 2016; 38 (3): 265–9. DOI: 10.1016/j.jogc.2016.01.008
50. Elbiaa AAM, Abdelazim IA, Farghali MM, et al. Unexpected premalignant gynecological lesions in women undergoing vaginal hysterectomy for utero-vaginal prolapse. Prz menopauzalny = Menopause Rev. 2015; 14 (3): 188–91. DOI: 10.5114/pm.2015.54344
51. Grigoriadis T, Valla A, Zacharakis D, et al. Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy? Int Urogynecol J. 2015; 26 (3): 421–5. DOI: 10.1007/s00192-014-2516-5
52. Mahajan G, Kotru M, Batra M, et al. Usefulness of histopathological examination in uterine prolapse specimens. Aust N Z J Obstet Gynaecol. 2011; 51 (5): 403–5. DOI: 10.1111/j.1479-828X.2011.01337.x
53. Chung CP, Lee SJ, Wakabayashi MT. Uterine and cervical cancer with irreducible pelvic organ prolapse. Am J Obstet Gynecol. 2018; 219 (6): 621–2. DOI: 10.1016/j.ajog.2018.05.021
54. Babarović E, Sladoljev K, Perin E, et al. Primary Carcinosarcoma of the Vagina Associated With Differentiated Squamous Intraepithelial Neoplasia in a Patient With Complete Uterine Prolapse: Case Report and Review of the Literature. Int J Surg Pathol. 2018; 26 (4): 370–6. DOI: 10.1177/1066896917745592
55. Martin C, Hong L, Siddighi S. What is hiding behind the pessary? Int Urogynecol J. 2013; 24 (5): 873–5. DOI: 10.1007/s00192-012-1864-2
56. Iavazzo C, Vorgias G, Vecchini G, et al. Vaginal carcinoma in a completely prolapsed uterus. A case report. Arch Gynecol Obstet. 2007; 275 (6): 503–5.
DOI: 10.1007/s00404-006-0284-2
57. Reimer D, Sztankay A, Steppan I, et al. Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. Eur J Gynaecol Oncol. 2008; 29 (3): 272–5.
58. Ramaseshan AS, Felton J, Roque D, et al. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. Int Urogynecol J. 2018; 29 (4): 459–76. DOI: 10.1007/s00192-017-3467-4
Авторы
М.Р. Оразов*, Л.Р. Токтар, Г.А. Каримова, В. Пак, К. Ли, И.А. Муллина
ФГАОУ ВО «Российский университет дружбы народов», Москва, Росси
*omekan@mail.ru
People’s Friendship University of Russia, Moscow, Russia
*omekan@mail.ru
ФГАОУ ВО «Российский университет дружбы народов», Москва, Росси
*omekan@mail.ru
________________________________________________
People’s Friendship University of Russia, Moscow, Russia
*omekan@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.